Format

Send to

Choose Destination
Rev Esp Med Nucl Imagen Mol. 2017 Nov - Dec;36(6):396-398. doi: 10.1016/j.remn.2017.02.010. Epub 2017 May 4.

Diagnosing neuroleukemiosis: Is there a role for 18F-FDG-PET/CT?

[Article in English, Spanish]

Author information

1
PET Unit, Department of Nuclear Medicine - IDI, Hospital Universitari de Bellvitge - IDIBELL, L'Hospitalet de Llobregat, Barcelona, Spain. Electronic address: asabatell@bellvitgehospital.cat.
2
PET Unit, Department of Nuclear Medicine - IDI, Hospital Universitari de Bellvitge - IDIBELL, L'Hospitalet de Llobregat, Barcelona, Spain.
3
Hematologic Citology, Department of Pathology, Hospital Universitari de Bellvitge - IDIBELL, L'Hospitalet de Llobregat, Barcelona, Spain.
4
Department of Radiology - IDI, Hospital Universitari de Bellvitge - IDIBELL, L'Hospitalet de Llobregat, Barcelona, Spain.

Abstract

An imaging case is presented on a patient referred to our department for an 18F-FDG-PET/CT, as a paraneoplastic syndrome was suspected due to his clinical situation. He had a history of acute myeloid leukemia (AML) treated two years earlier, with sustained complete remission to date. 18F-FDG-PET/CT findings revealed hypermetabolism in almost all nerve roots, suggesting meningeal spread, consistent with the subsequent MRI findings. Cerebrospinal fluid (CSF) findings confirmed a leptomeningeal reactivation of AML. Although not many studies have evaluated the role of 18F-FDG-PET/CT in leukemia, it is a noninvasive tool for detecting extramedullary sites of disease and a good imaging alternative for those patients on whom an MRI cannot be performed.

KEYWORDS:

Acute myeloid leukemia; FDG; Leucemia mieloide aguda; Meningeal relapse; Neuroleucemiosis; Neuroleukemiosis; PET/CT; PET/TC; Recidiva meníngea

PMID:
28479262
DOI:
10.1016/j.remn.2017.02.010
[Indexed for MEDLINE]
Free full text

Supplemental Content

Full text links

Icon for Elsevier Science Icon for Ediciones Doyma, S.L.
Loading ...
Support Center